Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Publication year range
1.
Clin Transl Sci ; 10(3): 172-177, 2017 05.
Article in English | MEDLINE | ID: mdl-28482130

ABSTRACT

Cholesterol-lowering response to 40 mg simvastatin daily for 6 weeks was examined for associations with common genetic polymorphisms in key genes affecting simvastatin metabolism (CYP3A4 and CYP3A5) and transport (SLCO1B1). In white people (n = 608), SLCO1B1 521C was associated with lesser reductions of total and low-density lipoprotein cholesterol. Associations between SLCO1B1 521C and cholesterol response were not detected in African Americans (n = 333). Associations between CYP3A4*22 or CYP3A5*3 and cholesterol response were not detected in either race, and no significant race-gene or gene-gene interactions were detected. As several of the analyses may have been underpowered (especially the analyses in the African American cohort), the findings not suggesting an association should not be considered conclusive and warrant further investigation. The finding regarding SLCO1B1 521C in whites was consistent with several previous reports. SLCO1B1 521C resulted in a diminished cholesterol-lowering response, but a marginal effect size limits utility for predicting simvastatin response.


Subject(s)
Cholesterol/blood , Cytochrome P-450 CYP3A/genetics , Genetic Association Studies , Liver-Specific Organic Anion Transporter 1/genetics , Polymorphism, Single Nucleotide/genetics , Simvastatin/pharmacology , Female , Humans , Male , Middle Aged
2.
Pharmacogenomics J ; 17(3): 222-229, 2017 06.
Article in English | MEDLINE | ID: mdl-26927283

ABSTRACT

Statins are widely prescribed to lower plasma low-density lipoprotein (LDL) cholesterol levels. They also modestly reduce plasma triglyceride (TG), an independent cardiovascular disease risk factor, in most people. The mechanism and inter-individual variability of TG statin response is poorly understood. We measured statin-induced gene expression changes in lymphoblastoid cell lines derived from 150 participants of a simvastatin clinical trial and identified 23 genes (false discovery rate, FDR=15%) with expression changes correlated with plasma TG response. The correlation of insulin-induced gene 1 (INSIG1) expression changes with TG response (rho=0.32, q=0.11) was driven by men (interaction P=0.0055). rs73161338 was associated with INSIG1 expression changes (P=5.4 × 10-5) and TG response in two statin clinical trials (P=0.0048), predominantly in men. A combined model including INSIG1 expression level and splicing changes accounted for 29.5% of plasma TG statin response variance in men (P=5.6 × 10-6). Our results suggest that INSIG1 variation may contribute to statin-induced changes in plasma TG in a sex-specific manner.


Subject(s)
Dyslipidemias/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Intracellular Signaling Peptides and Proteins/genetics , Lymphocytes/drug effects , Membrane Proteins/genetics , Pharmacogenomic Variants , Simvastatin/therapeutic use , Triglycerides/blood , Adult , Aged , Cell Line , Dyslipidemias/blood , Dyslipidemias/diagnosis , Dyslipidemias/genetics , Female , Gene Expression Regulation , Humans , Intracellular Signaling Peptides and Proteins/metabolism , Lymphocytes/metabolism , Male , Membrane Proteins/metabolism , Middle Aged , Pharmacogenetics , Sex Factors , Treatment Outcome
3.
Pharmacogenomics J ; 17(2): 137-145, 2017 03.
Article in English | MEDLINE | ID: mdl-26856248

ABSTRACT

Variation in the expression level and activity of genes involved in drug disposition and action ('pharmacogenes') can affect drug response and toxicity, especially when in tissues of pharmacological importance. Previous studies have relied primarily on microarrays to understand gene expression differences, or have focused on a single tissue or small number of samples. The goal of this study was to use RNA-sequencing (RNA-seq) to determine the expression levels and alternative splicing of 389 Pharmacogenomics Research Network pharmacogenes across four tissues (liver, kidney, heart and adipose) and lymphoblastoid cell lines, which are used widely in pharmacogenomics studies. Analysis of RNA-seq data from 139 different individuals across the 5 tissues (20-45 individuals per tissue type) revealed substantial variation in both expression levels and splicing across samples and tissue types. Comparison with GTEx data yielded a consistent picture. This in-depth exploration also revealed 183 splicing events in pharmacogenes that were previously not annotated. Overall, this study serves as a rich resource for the research community to inform biomarker and drug discovery and use.


Subject(s)
Alternative Splicing , Computational Biology , High-Throughput Nucleotide Sequencing , Pharmacogenetics , Pharmacogenomic Variants , Sequence Analysis, RNA , Transcriptome , Adipose Tissue/metabolism , Cell Line , Databases, Genetic , Genotype , Humans , Kidney/metabolism , Liver/metabolism , Myocardium/metabolism , Phenotype
5.
Pharmacogenomics J ; 15(3): 272-7, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25266681

ABSTRACT

Several reports have shown that statin treatment benefits patients with asthma; however, inconsistent effects have been observed. The mir-152 family (148a, 148b and 152) has been implicated in asthma. These microRNAs suppress HLA-G expression, and rs1063320, a common SNP in the HLA-G 3'UTR that is associated with asthma risk, modulates miRNA binding. We report that statins upregulate mir-148b and 152, and affect HLA-G expression in an rs1063320-dependent fashion. In addition, we found that individuals who carried the G minor allele of rs1063320 had reduced asthma-related exacerbations (emergency department visits, hospitalizations or oral steroid use) compared with non-carriers (P=0.03) in statin users ascertained in the Personalized Medicine Research Project at the Marshfield Clinic (n=421). These findings support the hypothesis that rs1063320 modifies the effect of statin benefit in asthma, and thus may contribute to variation in statin efficacy for the management of this disease.


Subject(s)
Asthma/drug therapy , Asthma/genetics , HLA-G Antigens/genetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Polymorphism, Single Nucleotide/genetics , 3' Untranslated Regions/genetics , Alleles , Cell Line, Tumor , Female , Hep G2 Cells , Humans , Male , MicroRNAs/genetics , Middle Aged , Risk
6.
Eur J Clin Nutr ; 69(2): 147-53, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25335444

ABSTRACT

BACKGROUND/OBJECTIVES: It is estimated that zinc deficiency affects 17% of the world's population, and because of periods of rapid growth children are at an increased risk of deficiency, which may lead to stunting. This paper presents a systematic review and meta-analysis of the randomised controlled trials (RCTs) that assess zinc intake and growth in children aged 1-8 years. This review is part of a larger systematic review by the European Micronutrient Recommendations Aligned Network of Excellence that aims to harmonise the approach to setting micronutrient requirements for optimal health in European populations (www.eurreca.org). SUBJECT/METHODS: Searches were performed of literature published up to and including December 2013 using MEDLINE, Embase and the Cochrane Library databases. Included studies were RCTs in apparently healthy child populations aged from 1 to 8 years that supplied zinc supplements either as capsules or as part of a fortified meal. Pooled meta-analyses were performed when appropriate. RESULTS: Nine studies met the inclusion criteria. We found no significant effect of zinc supplementation of between 2 weeks and 12 months duration on weight gain, height for age, weight for age, length for age, weight for height (WHZ) or WHZ scores in children aged 1-8 years. CONCLUSIONS: Many of the children in the included studies were already stunted and may have been suffering from multiple micronutrient deficiencies, and therefore zinc supplementation alone may have only a limited effect on growth.


Subject(s)
Body Height/drug effects , Body Weight/drug effects , Deficiency Diseases , Dietary Supplements , Growth Disorders/etiology , Trace Elements/pharmacology , Zinc/pharmacology , Child , Deficiency Diseases/drug therapy , Europe , Growth/drug effects , Growth Disorders/prevention & control , Humans , Trace Elements/deficiency , Trace Elements/therapeutic use , Zinc/deficiency , Zinc/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL